Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02485691
Recruitment Status : Completed
First Posted : June 30, 2015
Last Update Posted : March 30, 2021
Sponsor:
Information provided by (Responsible Party):
Sanofi